We are live on ! Find out more
TWST icon

Twist Bioscience

239 hedge funds and large institutions have $5.82B invested in Twist Bioscience in 2021 Q1 according to their latest regulatory filings, with 50 funds opening new positions, 91 increasing their positions, 75 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

56% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 32

21% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 75

8% more funds holding

Funds holding: 222239 (+17)

6.97% more ownership

Funds ownership: 89.64%96.61% (+7%)

4% less capital invested

Capital invested by funds: $6.06B → $5.82B (-$244M)

29% less call options, than puts

Call options by funds: $21.6M | Put options by funds: $30.3M

56% less funds holding in top 10

Funds holding in top 10: 94 (-5)

Holders
239
Holders Change
+17
Holders Change %
+7.66%
% of All Funds
4.2%
Holding in Top 10
4
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-55.56%
% of All Funds
0.07%
New
50
Increased
91
Reduced
75
Closed
32
Calls
$21.6M
Puts
$30.3M
Net Calls
-$8.72M
Net Calls Change
-$4.32M
Name Holding Trade Value Shares
Change
Change in
Stake
PP
76
PDT Partners
New York
$3.51M -$174K -1,147 -4%
IP
77
Intellectus Partners
California
$3.48M
PPA
78
Parametric Portfolio Associates
Washington
$3.34M +$152K +1,001 +4%
CIA
79
Capital Impact Advisors
Massachusetts
$3.33M -$10.6M -70,108 -72%
CFM
80
Comprehensive Financial Management
California
$3.25M -$2.44M -16,090 -38%
Manulife (Manufacturers Life Insurance)
81
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$3.23M +$988K +6,504 +33%
Jane Street
82
Jane Street
New York
$3.08M -$3.55M -23,391 -48%
AIM
83
Aigen Investment Management
New York
$2.98M +$3.65M +24,068 New
Rafferty Asset Management
84
Rafferty Asset Management
New York
$2.92M +$2.58M +16,973 +258%
SG Americas Securities
85
SG Americas Securities
New York
$2.89M +$3.38M +22,257 +2,048%
BHCM
86
Brevan Howard Capital Management
Jersey
$2.81M -$13.6M -89,289 -80%
KOC
87
Koss-Olinger Consulting
Florida
$2.66M +$3.26M +21,500 New
VF
88
Virtu Financial
New York
$2.6M +$2.29M +15,070 +253%
N
89
Natixis
France
$2.57M -$361K -2,379 -10%
VOYA Investment Management
90
VOYA Investment Management
Georgia
$2.54M +$940K +6,191 +43%
GC
91
Guggenheim Capital
Illinois
$2.5M +$353K +2,327 +13%
State of New Jersey Common Pension Fund D
92
State of New Jersey Common Pension Fund D
New Jersey
$2.49M -$436K -2,869 -12%
Macquarie Group
93
Macquarie Group
Australia
$2.47M +$2.86M +18,850 +1,686%
ProShare Advisors
94
ProShare Advisors
Maryland
$2.39M +$768K +5,056 +36%
RI
95
RTW Investments
New York
$2.29M
Russell Investments Group
96
Russell Investments Group
United Kingdom
$2.26M -$916K -6,034 -25%
EF
97
Empowered Funds
Pennsylvania
$2.23M
MIM
98
MetLife Investment Management
New Jersey
$2.16M +$607K +3,997 +30%
AP
99
AlpInvest Partners
Netherlands
$2.13M +$2.61M +17,189 New
BM
100
Brandywine Managers
Delaware
$2.08M -$328K -2,160 -11%

TWST Hedge Fund Activity: Q1 2021 in Review

239 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Twist Bioscience (TWST) for Q1 2021, worth a combined $5.82B — down 4% from $6.06B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new TWST positions and 32 closed out — a net gain of 18 holders — while 91 added to existing stakes and 75 trimmed.

The largest buyer was Allianz Asset Management, adding an estimated $242M. The largest seller was Lord, Abbett & Co, cutting an estimated $62.6M.

  • 239 institutional investors held Twist Bioscience (TWST) as of Q1 2021, up from 222 in Q4 2020.
  • Funds reported $5.82B of Twist Bioscience stock for Q1 2021, down 4% quarter-over-quarter.
  • 50 funds opened new Twist Bioscience positions in Q1 2021 and 32 closed out, a net change of +18 holders.
  • The largest Twist Bioscience buyer in Q1 2021 was Allianz Asset Management, an estimated $242M added.
  • The largest Twist Bioscience seller in Q1 2021 was Lord, Abbett & Co, an estimated $62.6M sold.

Based on aggregated 13F filings for Q1 2021.